Le Lézard
Classified in: Health
Subject: FDA

FDA Approves SOAANZ for Edema Treatment in Patients with Heart Failure and Renal Disease

VIENNA, Va., June 21, 2021 /PRNewswire-PRWeb/ -- Sarfez Pharmaceuticals announced today approval by the U.S. Food and Drug Administration (FDA) of the Virginia-based company's New Drug Application for Soaanz®, a once-a-day improved formulation of the loop diuretic torsemide. The approved drug provides a new treatment option for patients suffering from heart failure who experience persistent edema, swelling in the lower limbs and/or abdomen, despite a loop diuretic therapy. Soaanz provides a longer duration of peak effects without causing excessive urination.

"Soaanz is specifically formulated to reduce excessive urination in heart failure patients. We believe that for many of these patients who are aged 65 and older, the new treatment option now approved by the FDA offers tremendous benefits," said Salim Shah, PhD, JD, Founder and Chairman, Sarfez Pharmaceuticals. "We look forward to launching Soaanz in the next few months, bringing an effective new treatment option to heart failure patients."

Soaanz offers an alternative treatment for heart failure patients who skip loop diuretic treatment due to concerns with excessive urination, as well as patients with chronic kidney disease. Loop diuretics are the drug of choice for the treatment of volume overload caused by heart failure and chronic kidney disease. Soaanz is an oral once-a-day tablet with an extended duration of peak effect and with a longer time to reach the peak effect.

"Sarfez Pharmaceuticals benefited from grant funding made available by the Small Business Administration and National Institute of Diabetes and Digestive and Kidney Diseases during our development of Soaanz," said Dr. Shah. "We are thankful for that support, and we plan to transfer that benefit on to our patients by offering Soaanz at a reasonable price. This was an important decision for our team to make because most heart failure patients are insured under Medicare programs and have limited disposable income. We feel that lowering our costs to help improve care for these patients is our obligation as a healthcare company."

For more information on Soaanz, please visit: https://www.sarfezpharma.com/soaanz 

About Sarfez Pharmaceuticals
Sarfez Pharmaceuticals is headquartered in Vienna, VA. The pharmaceutical research and development company is focused on improving existing drugs to provide better treatment options for cardio-renal diseases. Sarfez Pharmaceuticals is dedicated to creating better treatment options and reducing drug costs by improving existing cardiovascular drugs, offering them at reasonable prices and with greater transparency.

Forward-looking Statement
Some statements are forward-looking. For these statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. There are many factors that could cause our actual statements to differ materially thus, any forward-looking statements contained in this press release speak only as of the date hereof, and Sarfez expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Media Contact

Salim Shah, Sarfez Pharmaceuticals Inc, +1 7036271934, salim.shah@sarfez.com


SOURCE Sarfez Pharmaceuticals Inc

These press releases may also interest you

at 16:20
In the Phase 3 VALOR study, the primary endpoint as measured by the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) did not reach statistical significance; however, signs of reduced disease progression across multiple...

at 16:20
Ionis Pharmaceuticals, Inc. partner Biogen today announced topline results from its placebo-controlled pivotal Phase 3 VALOR study of tofersen (BIIB067), an investigational antisense medicine being evaluated for people with superoxide dismutase 1...

16 oct 2021
Core One Labs Inc. , , (the "Company") a research and technology company focused in life sciences and on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy, congratulates Seattle's city...

16 oct 2021
Neurocrine Biosciences, Inc.  today announced that it will present key information from its movement disorder treatments for Parkinson's disease and tardive dyskinesia (TD) at the American Neurological Association (ANA) 2021 Virtual Annual Meeting...

16 oct 2021
HLNY's highest recognition, the "Award of Distinction" will be presented to Arthur Gianelli, FACHE, Chief Transformation Officer of Mount Sinai Health System and President of Mount Sinai Morningside. This award recognizes a healthcare executive who...

16 oct 2021
Regulated Information ? Inside Information ? UCB, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that they were unable to complete review of the Biologics License...

News published on 21 june 2021 at 11:00 and distributed by: